By Momo Yamamoto, Investor Research Analyst, LSN
Life Science Nation(LSN)’s research team has been inviting investors to attend the upcoming RESI South conference and there are some exciting new life sciences, early-stage focused investors who will be joining the RESI South conference.
 |
 |
 |
 |
 |
 |
 |
MSL Investment |
 |
|
Some new investors attending RESI South include Caduceus Capital Partners, a venture capital firm based in Nashville, TN that invests in early-stage digital health companies across the US. A managing partner of the firm will also be speaking on the Digital Health panel. Joining that panel is another managing partner from Bullet Partners, a private equity and advisory firm headquartered in Atlanta, GA that focuses on digital health and SaaS companies. Monday Capital, a venture capital firm headquartered in New York that invests in biotechnology and digital health companies focused on longevity, blockchain infrastructure, and AI in Seed and early venture rounds, will also be attending for the first time and will be on the AI in Healthcare panel. Pier 70 Ventures, a venture capital firm based in Seattle, WA that invests in digital health and therapeutics companies in seed and early growth rounds will also be joining the discussion on the AI in Healthcare panel as well. GRA Venture Fund, a public-private venture capital fund investing in research-driven, Georgia-based startup companies will also be attending RESI South for the first time in-person. Boyd Street Ventures, a venture capital firm headquartered in Oklahoma that invests in life sciences and healthtech and is preparing to launch its second fund later this year, will be attending in-person. Catalyst by Wellstar, a fund affiliated with Gerogia’s largest healthcare system, and MSL Investments, an early-stage investment firm focused on early-stage medtech and digital health companies, will be attending virtually. Ajinomoto Corporate Venture Capital (Ajinomoto CVC) is the corporate venture arm of Ajinomoto Co., Inc., a leading global company well known for its food products and amino science businesses with over $10B revenue. Ajinomoto CVC was launched in 2020 and has a US office based in Palo Alto, CA. The firm seeks to make equity investments in promising early-stage biotech companies developing therapeutics of novel modalities companies, in mostly Seed and Series A rounds.
Next Phase Newsletter 
Leave a comment